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Abstract
We investigated polymorphisms of plasminogen activator inhibitor-1 (PAI-1), angiotensin converting enzyme (ACE ) and
coagulation factor XIII (FXIII) genes and their association with recurrent spontaneous abortion (RSA) in Iranian patients
and normal healthy controls. Ten (18.5%) patients were homozygote (4G/4G) for PAI-1 polymorphism, in contrast with two
(2%) controls (p¼ 0.001). Patients with homozygote 4G mutation were significantly more prone to RSA in contrast to
others (odds ratio: 11.0, 95% CI: 2.3–52.4). Nineteen (30.2%) patients and 25 (26.6%) controls were homozygote (DD) for
ACE polymorphism. We observed only two patients and one control with homozygosity (34leu) for FXIII polymorphism.
4G/4G polymorphism for PAI-1 gene could be a thrombophilic mutation leading to abortion in Iranian population.
Keywords: Recurrent spontaneous abortion, thrombophilia, plasminogen activator inhibitor-1, angiotensin converting enzyme,
coagulation factor XIII
Introduction
Recurrent spontaneous abortion (RSA) is among the most
common complications of pregnancy, affecting more than
5% of women. It might cause considerable emotional
distress in couples who desire to have children. The
etiology of RSA remains unexplained in many patients, but
about 55% of patients are suspected to be associated with
thrombophilic defects [1].
Thrombophilia can be characterized as an increased
tendency towards thrombosis through enhanced coagula-
tion. It includes several rare inherited abnormalities, often
leading to thrombosis in young people [2]. Thrombophilia
is shown to be associated with venous thromboembolism,
deep vein thrombosis, pulmonary embolism, myocardial
infarction and cerebral vein thrombosis [1,2].
Pregnancy is stable when there is a balance between
maternal coagulation and fibrinolysis. This balance pre-
vents excess fibrin deposition in placental vessels and
intravillous spaces, secures fibrin polymerization and
stabilizes the placental basal plate [3]. Women with
thrombophilic defects are at increased risk, not only for
pregnancy associated thromboembolism, but also for other
vascular complications, such as pre-eclampsia and fetal
loss [2].
Homeostasis abnormalities could be due to heritable or
acquired defects which lead to clinical thrombophilia.
Inherited abnormalities include mutations of either the
genes encoding natural anticoagulants like antithrombin
III, proteins C and S [1], or clotting factors like
prothrombin, factor V Leiden (FVL) and methylenetetra-
hydrofolate reductase (MTHFR) [4].
In addition to above genetic defects, polymorphisms of
plasminogen activator inhibitor-1 (PAI-1), coagulation
factor XIII (FXIII) and angiotensin converting enzyme
(ACE) genes have been mentioned. These genes appear to
be a cause of impaired fibrinolysis which could promote
the development of RSA [5].
PAI-1 has a vital role in hypofibrinolysis and thrombotic
complications. The gene expression is modulated by a
4G/5G polymorphism in the promoter region, which is
located 675 bp upstream from the start site of transcription
[6]. The 4G allele binds to transcription-regulating factors
and produces more PAI-1 protein than 5G allele. High
levels of PAI-1 concentration could result in increased
thrombosis through the defect in fibrinolysis and coagula-
tion. This can contribute to initiation of placental damage
and thrombotic complication [7].
ACE regulates thrombosis through generating angioten-
sin II from angiotensin I [2]. In addition, ACE is a key
component of the rennin–angiotensin system and affects
homeostasis [3].The level of enzyme is related to poly-
morphism of ACE gene consisting of the insertion/
deletion (I/D) of a 287-bp fragment in intron 16 [8].
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Blood FXIII plays an important role in fibrin stabiliza-
tion and protection of fibrin from proteolytic degradation.
It is a pro-transglutaminase of tetrameric structure (A2B2)
consisting of two potentially active A subunits (FXIII-A)
and two inhibitory/protective B subunits (FXIII-B) [7].
The Val34Leu polymorphism in exon 2 of the FXIII-A
gene could have an antifibronolytic effect through the early
cross-linking of fibrin fibers [9].
In this study, we have investigated the association of
RSA and PAI-1 4G/5G, ACE D/I and FXIII Val 34 Leu
polymorphisms in Iranian patients and healthy controls.
Methods
Patients
Patients with a history of spontaneous abortion and healthy
women without history of abortion as control group were
registered in Avicenna Infertility Clinic and Department of
Obstetrics & Gynecology of Imam Hospital, Tehran, Iran.
The inclusion criterion was having the experience of at
least three unexplained consecutive spontaneous abortions
before 25 weeks of gestation. We also studied the patients
with two unexplained consecutive spontaneous abortions
before 25 weeks of gestation. For all patients, we collected
medical history as well as results of physical examination,
routine laboratory, endocrinologic and immunological
tests for autoantibodies from the database of above centers.
We excluded patients with known risk factors for sponta-
neous abortion: anatomical abnormalities, endocrinologic
dysfunctions, autoimmune diseases, urogenital infection
and inflammatory pelvic disease. All patients and normal
healthy controls were Iranian.
Approval from the Avicenna Research Institute’s ethics &
human rights committee was obtained for the use of blood
samples and study protocol. Before study, all participants
signed the informed consent form.
Determination of genotype
To analyze the D/I polymorphism in intron 16 of the ACE
gene and the 7675 4G/5G polymorphism in the promoter
region of the PAI-1 gene and Val 34 Leu FXIII
polymorphisms, 5 ml of blood samples were obtained.
Genomic DNA was then extracted from leukocytes using
salting out standard protocol. Genomic DNA was ampli-
fied by polymerase chain reaction (PCR) using gene-
specific primers (Figure 1).
Each 25 ml of reaction contained 2.5 ml of 106PCR
reaction buffer (100 mM Tris-HCl, 500 mM KCl pH:
8.3), 1.5 ml MgCl2 (25 mM), 1 ml of forward and reverse
primers (10 mM), 1U DNA polymerase (5U, ROCHE,
Mannheim, Germany) and 150 ng of DNA. After dena-
turation at 948C for 5 min, DNA fragments were either
amplified for 35 cycles for FXIII (948C for 30 s, 588C for
30 s and 728C for 30 s), 35 cycles for ACE (948C for 30 s,
708C for 40 s and 728C for 1 min), and 32 cycles for PAI-1
polymorphisms (948C for 30 s, 608C for 30 s and 728C for
1 min). PCR cycles were followed by final extension step at
728C for 7 min.
For the amplification of PAI-1 gene, we designed a
forward primer different from the native sequence in order
to introduce a site for BseR I restriction enzyme.
Originally, the 148 bp PCR product has no restriction site
for enzyme, but combination of nucleotide substitution
and genetic abnormality creates the enzyme cleavage site
and cleaves the amplicon into two fragments (110 bp and
38 bp). The D/I genotype of the ACE gene was described
by 190 bp PCR product length in deletion, as well as
490 bp in insertion. Finally, PCR product of FXIII Val 34
Leu polymorphism had a length of 192 bp with no
restriction site for DdeI enzyme. The mutation in FXIII
created a restriction site and produced two fragments
(161 bp and 31 bp) after enzyme digestion.
PCR products were separated on 1.5% agarose gel and
visualized by ethidium bromide staining under UV light.
Digested and undigested PCR products were separated by
polyacrylamide gel electrophoresis (PAGE) and visualized
using silver staining method.
Statistical methods
Patients were categorized according to their genotypes.
Statistical analysis was performed with the Statistical
Package for Social Sciences (SPSS, version 16 for
Windows, Chicago, IL). Results of the two groups were
compared using Fisher’s exact test or w2 test, as well as
t-test for quantitative variables. An a level of 0.05 was used
to indicate statistical significance. We firstly compared
Figure 1. Genotyping assays for PAI-1, ACE and factor XIII polymorphisms. Primer sequences are listed from 50 to 30, and the upper
sequence represents the forward primer; the lower sequence, the reverse primer. The underlined bases were changed from the native
sequence to introduce a restriction enzyme recognition sequence that would result in digestion of the PCR product to the fragments shown
in parentheses.
546 M. Aarabi et al.
J M
at
er
n 
Fe
ta
l N
eo
na
ta
l M
ed
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f G
la
sg
ow
 o
n 
05
/0
6/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
patients with RSA (3 abortions) and controls. In the next
step, the comparison was done for patients with two or
more abortions and controls.
Results
After excluding the patients with known risk factors of
spontaneous abortion, we investigated 63 patients and 114
healthy women of the control group for the PAI-1, ACE,
and FXIII gene polymorphisms. Mean age at registration
was 32.5 (95% CI: 31.1–34.0) years for patients and
32.9(95% CI: 31.4–34.5) years for controls. The difference
between ages in patient population versus the control group
was not statistically significant (T-Test, p¼ 0.01). Mean
frequency of abortion among 63 patients was 4.6 (95% CI:
4.0–5.3) with a range of 3–15. Neither physical examina-
tion nor laboratory tests were significantly different among
patient and control groups.
The incidence of the PAI-1 4G/5G polymorphism in
patients was 10 (18.5%) for homozygous 4G, 23 (42.6%)
for heterozygous 4G/5G and 21 (38.9%) for homozygous
5G versus 2 (2.0%), 66 (66.7%) and 31 (31.3%) in
controls, respectively. The prevalence of polymorphism
(4G/4G) in patients was significantly higher than controls
(w2 test: p¼ 0.001). Patients with homozygote 4G/4G
polymorphism were significantly more prone to RSA in
contrast to controls (OR: 11.0, 95% CI: 2.3–52.4)
(Table I). Interestingly, the frequency of 4G polymorphism
was higher among the participants with two or more
abortions rather than controls (w2 test: p¼ 00.1). We found
that this polymorphism could result in the higher risk of
having two or more abortions in our study population (OR:
8.2, 95% CI: 1.8–36.5) (Table II).
The frequency of ACE D/I polymorphism in patients
was 14 (22.2%) for homozygous II, 30 (47.6%) for
heterozygous DI and 19 (30.2%) for homozygous DD;
whereas the frequency in the control group was 22
(23.4%), 47 (50%) and 25 (26.6%), respectively. The rate
of mutation in patients was not statistically higher than
control group.
FXIII 34Val, Val 34Leu, and 34Leu genotypes were
observed in 71.9%, 24.6% and 3.5% of patients, respec-
tively. There was no significant difference between patients
and controls (Figure 2).
We also combined the results of polymorphisms of above
three genes to find any probable differences between
patients and controls. However, we were unable to find any
significant associations. More details of results are shown
in Tables I and II.
Discussion
Polymorphism analysis of genes involved in thrombophilia
should be investigated in different ethnics. Detection of
those polymorphisms with RSA can help clinicians to
design better therapeutic strategies.
In this study, we observed the significant increase of
PAI-1 (4G/4G) polymorphism in patients with RSA.
Table I. Frequency of homozygous mutations in patient group and
controls.
Patients Controls
OR
No. Fr. No. Fr. p value (CI 95%)
PAI-1 10 18.5 2 2.0 0.001 11.0 (2.3–52.4)
ACE 19 30.2 25 26.6 0.626 1.2 (0.6–2.4)
FXIII 2 3.5 1 0.9 0.277 3.9 (0.3–43.5)
PAI-1&ACE 2 3.3 0 0 0.125 NS
PAI-1&FXIII 0 0 0 0 NS NS
ACE&FXIII 0 0 0 0 NS NS
PAI-1&ACE&FXIII 0 0 0 0 NS NS
OR, odds ratio; CI, confidence interval; Fr., frequency; NS, not
significant.
Table II. Frequency of homozygous mutations in participants with
two or more spontaneous abortions and controls.
Patients Controls
OR
No. Fr. No. Fr. p value (CI 95%)
PAI-1 16 14.4 2 2.06 0.001 8.2 (1.8–36.5)
ACE 38 29.5 25 26.6 0.639 1.2 (0.7–2.1)
FXIII 2 1.7 1 0.9 1 1.8 (0.2–20.1)
PAI-1&ACE 3 2.4 0 0 0.25 NS
PAI-1&FXIII 0 0 0 0 NS NS
ACE&FXIII 0 0 0 0 NS NS
PAI-1&ACE&FXIII 0 0 0 0 NS NS
OR, odds ratio; CI, confidence interval; Fr. Frequency; NS, not
significant.
Figure 2. PCR products of thrombophilic mutations among patients with RSA. M: marker, 1: homozygote patient, 2: normal heterozygote,
3: normal homozygote (A: PAI-1, B: ACE, C: FXIII).
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We also found this polymorphism as a risk factor for
spontaneous abortion. Three-fold elevations in the level of
functionally active plasminogen have been reported as a
risk factor for pregnancy disorders and fetal damage [6]. In
addition, Kohler has described higher concentrations of
PAI-1 as well as increased frequency of PAI-1 4G/4G
genotype in patients with myocardial infarction [10]. Their
data suggested that the PAI-1 4G and FXIII 34Leu
variants synergistically contribute to impaired fibrinolysis
because of reduced activity of the fibrinolytic system and
increased resistance of the fibrin network to fibrinolysis
[7,10]. Our data support parts of their suggestion that PAI-
1 4G variant might be a risk factor for recurrent abortion,
but does not support the role of FXIII 34Leu. On the other
hand, our findings are supported by other studies which
reported the elevated plasminogen activator inhibitor type
1 (PAI-1) and PAI-1 polymorphisms [7] in patients with
RSA and thrombotic homeostasis defects. This may
promote the development of early pregnancy loss in
affected women by insufficient trophoblast invasion
and unbalanced fibrin deposition in the early placental
circulation.
We considered three or more spontaneous abortions as
the definition of RSA in this study. However, we found that
the PAI-1 4G polymorphism is even more frequent among
participants with two or more abortions over the controls.
This finding highlights the important role of 4G poly-
morphism as a potential risk factor of spontaneous
abortion. We recommend the screening of this polymorph-
ism not only for women with RSA, but for women with the
history of two or more spontaneous abortions.
We demonstrated that homozygosity for the ACE alleles
is not a risk factor for RSA in our population. The
difference of patterns of I/D polymorphism in ACE gene is
suggested to be an important risk factor for cardiovascular
morbidity and mortality in Western and Asian individuals.
This might be relevant in explaining differences of
thromboembolic diseases in different populations. ACE
D allele is demonstrated to be in association with increased
level of PAI-1 and susceptibility to fibrinolysis [8]. We
could not find any significant association between ACE
polymorphism as well as combination of polymorphisms
and RSA in our study. This finding could be due to the
differences between ethnicity of participating women in
studies. The strong association between the ethnicity of the
study population and the polymorphism frequencies is
possible and should be considered [11].
We previously analyzed the frequency of FVL
(G1691A), MTHFR (C677T), and FII (G20210A) muta-
tions in Iranian patients who suffered from unexplained
infertility or RSA and compared the results with healthy
controls. Those data showed a skew towards higher
mutation frequencies of FVL and MTHFR in the patients
[4]. Investigation of the cumulative risk associated with a
combination of those three mutations and sequence
variants of the PAI-1, ACE and FXIII genes in our
patients revealed no association between above six poly-
morphisms as a risk factor for pregnancy loss.
This study along with our previous published data
emphasize that analysis of PAI-1 (4G/4G) polymorphism,
FVL (G1691A) and MTHFR (C677T) mutations should
be included in the routine work-up of patients with RSA.
The clinical implications of these data need to be
addressed in a prospective study to answer the question
whether or not homozygous individuals should be treated
with heparin to prevent RSA.
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